Skip to main content

Table 2 Characteristics of 1568 men entering the trial

From: Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621]

Characteristic Values
Age (average years [range]) 68.6 (35–92)
Smoking (n [%])  
   Current 593 (37.8)
   Ex 908 (57.9)
   Never 67 (4.3)
Previous history (n [%])*  
   Myocardial infarction 332 (21.2)
   Stroke 194 (12.4)
   Stable angina 382 (24.4)
Blood pressure, mmHg (mean [SD])  
   Systolic 147.5 (21.7)
   Diastolic 77.1 (11.5)
Diabetes (n [%]) 268 (17.1)
Antiplatelet medication (n [%]) 1027 (65.5)
Fibrinogen, g/l (mean [SD]) 3.37 (0.60)
Total cholesterol, mmol/l (mean [SD]) 5.64 (0.93)
LDL-cholesterol, mmol/l (mean [SD]) 3.40 (0.86)
HDL-cholesterol, mmol/l (mean [SD]) 1.19 (0.36)
Triglycerides, mmol/l (mean [SD]) 2.40 (1.23)
  1. *Some men with more than one condition. Insulin (24%), oral therapy (57%) and diet only (22%). Aspirin (95%) and dipyridamole (5%).